How low can you go

Cholesterol, however, is essential to health. It is an important structural component of cell membranes, and it is also a sterol from which steroid hormones such as testosterone, estrogen, and progesterone are made. The liver is responsible for synthesizing most of the cholesterol found in the blood via the HMG Co-A (3-hydroxy-3-methylglutarylcoenzyme A) reductase pathway, but a diet that is high in saturated fats can increase cholesterol levels further, as can inheriting a genetic tendency towards having higher lipid levels.

[1]  S. Humphries,et al.  Familial hypercholesterolemia and coronary heart disease: a HuGE association review. , 2004, American journal of epidemiology.

[2]  Børge G Nordestgaard,et al.  PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. , 2010, Journal of the American College of Cardiology.

[3]  S. Kathiresan.  A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. , 2008, The New England journal of medicine.

[4]  Mark D. Huffman,et al.  Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[5]  Joel Stein,et al.  Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. , 2014, Circulation.

[6]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[7]  N. Papadopoulos,et al.  The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. , 2013, Atherosclerosis.

[8]  N. Jewell,et al.  Should people at low risk of cardiovascular disease take a statin? , 2013, BMJ.

[9]  Jonathan C. Cohen,et al.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. , 2006, American journal of human genetics.

[10]  W. Frishman,et al.  Antihyperlipidemic Therapies Targeting PCSK9 , 2014, Cardiology in review.

[11]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[12]  Annik Prat,et al.  The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR , 2007, Traffic.